NR2F1 and neoplasm: NR2F1 is associated with tumor dormancy in several tumor models (27, 29), and the BRAFi + MEKi drug-tolerant state exhibits traits similar to cellular dormancy, prompting us to test the link between NR2F1 and targeted therapy response.